Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrograde Autologous Priming and Mannitol for Hemoglobin Preservation
NCT04870073Phase 3Withdrawn
- Sponsor
- Hamilton Health Sciences
- Start
- Sep 2022
- Primary completion
- Sep 2022
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Bronchitol in hemodilution, sponsored by Hamilton Health Sciences. Primary endpoint: Feasibility Outcomes at 20 weeks. Planned start Sep 2022; status: withdrawn.
02
Drugs
Bronchitol
03
Conditions
hemodilution
Beyond the preview
Go deeper on NCT04870073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04870073.